Adelaide Research & Scholarship: Search

Search

Results 21-30 of 35 (Search time: 0.003 seconds).

previous
1
2
3
4
next

Item hits:

Preview	Issue Date	Title	Author(s)
	2003	Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia	O'Brien, S.; Guilhot, F.; Larson, R.; Gathmann, I.; Baccarani, M.; Cervantes, F.; Cornelissen, J.; Fischer, T.; Hochhaus, A.; Hughes, T.; Lechner, K.; Nielsen, J.; Rousselot, P.; Reiffers, J.; Saglio, G.; Shepherd, J.; Simonsson, B.; Gratwohl, A.; Goldman, J.; Kantarjian, H.; et al.
	2003	Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia	Hughes, T.; Kaeda, J.; Branford, S.; Rudzki, Z.; Hochhaus, A.; Hensley, M.; Gathmann, I.; Bolton, A.; van Hoomissen, I.; Goldman, J.; Radich, J.
	2009	Clinical strategies to achieve an early and successful response to tyrosine kinase inhibitor therapy	Hughes, T.; Hochhaus, A.
	2010	Nilotinib versus Imatinib for newly diagnosed chronic myeloid leukemia	Saglio, G.; Kim, D.; Issaragrisil, S.; le Coutre, P.; Etienne, G.; Lobo, C.; Pasquini, R.; Clark, R.; Hochhaus, A.; Hughes, T.; Gallagher, N.; Hoenekopp, A.; Haque, A.; Dong, M.; Larson, R.; Kantarjian, H.
	2004	Clinical resistance to imatinib: mechanisms and implications	Hochhaus, A.; Hughes, T.
	2012	Rac2-MRC-cIII-generated ROS cause genomic instability in chronic myeloid leukemia stem cells and primitive progenitors	Nieborowska-Skorska, M.; Kopinski, P.; Ray, R.; Hoser, G.; Ngaba, D.; Flis, S.; Cramer, K.; Reddy, M.; Koptyra, M.; Penserga, T.; Glodkowska-Mrowka, E.; Bolton, E.; Holyoake, T.; Eaves, C.; Cerny-Reiterer, S.; Valent, P.; Hochhaus, A.; Hughes, T.; Van der Kuip, H.; Sattler, M.; et al.
	2010	Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)	Hughes, T.; Hochhaus, A.; Branford, S.; Muller, M.; Kaeda, J.; Foroni, L.; Druker, B.; Guilhot, F.; Larson, R.; O'Brien, S.; Rudoltz, M.; Mone, M.; Wehrle, E.; Modur, V.; Goldman, J.; Radich, J.
	2009	Impact of baseline BCR-ABL mutations on response to Nilotinib in patients with chronic myeloid leukemia in chronic phase	Hughes, T.; Saglio, G.; Branford, S.; Soverini, S.; Kim, J.; Muller, M.; Martinelli, G.; Cortes, J.; Beppu, L.; Gottardi, E.; Dongho, K.; Erben, P.; Shou, Y.; Haque, A.; Gallagher, N.; Radich, J.; Hochhaus, A.
	2009	Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations	Muller, M.; Cortes, J.; Kim, D.; Druker, B.; Erben, P.; Pasquini, R.; Branford, S.; Hughes, T.; Radich, J.; Ploughman, L.; Mukhopadhyay, J.; Hochhaus, A.
	2011	Front-Line and Salvage Therapies With Tyrosine Kinase Inhibitors and Other Treatments in Chronic Myeloid Leukemia	Cortes, J.; Hochhaus, A.; Hughes, T.; Kantarjian, H.